Skip to main content
OpenTrials
Completed

NCT Number: NCT04646044

A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19

The main purpose of this phase-1b, multicenter, randomized double-blind, placebo-controlled, trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bempegaldesleukin (BEMPEG; NKTR-214) in combination with standard of care (SOC) in adult patients with mild COVID-19 (coronavirus disease 2019). The trial will also define the recommended phase 2 dose (RP2D) of bempegaldesleukin in patients with mild COVID-19.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Disease 2019 Coronavirus Infections Cytopenia Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunologic Deficiency Syndromes Infections Leukocyte Disorders Leukopenia Lung Diseases Lymphopenia Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

A G A Clinical Trials - HyperCore - PPDS, Hialeah, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female patients, age 18 years or older on the day of signing the informed consent form.
  • Agrees to admission to an in-patient facility for monitoring from Days 1 to 8, inclusive.
  • Symptoms of mild illness with COVID-19 without shortness of breath, dyspnea, or clinical signs indicative of more serious COVID-19.
  • Laboratory confirmed SARS-CoV-2 infection within 4 days prior to the screening visit or during the 7-day screening period.
  • Respiratory rate < 20 breaths per minute, heart rate < 90 beats per minute (bpm).
  • Oxygen saturation by pulse oximetry > 93% on room air.
  • Body mass index < 35 kg/m2.
  • Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min.
  • Alanine transaminase (ALT) or aspartate transaminase (AST) < 2 x upper limit of normal (ULN) and total bilirubin < 1.5 x ULN.
  • Agrees to not participate in another clinical trial for the treatment of COVID-19 while on study unless the patient's condition has worsened and is considered to be moderate, severe, or critical by the Investigator.

Exclusion criteria

  • Shortness of breath, hypoxia, or signs of serious lower airway disease.
  • C-reactive protein, lactate dehydrogenase (LDH), or interleukin-6 (IL-6) > 1.5 x ULN.
  • D-dimer or ferritin > 1.5 x ULN.
  • Imminently requiring, or currently on, mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
  • Systolic blood pressure < 90 mm Hg or diastolic blood pressure < 60 mm Hg.
  • Evidence of acute respiratory distress syndrome (ARDS) or systemic inflammatory response syndrome (SIRS)/shock.
  • Known cardiovascular history, including unstable or deteriorating cardiac disease.
  • Autoimmune disease.
  • History of pulmonary embolism (PE), deep vein thrombosis (DVT), or prior clinically significant venous or non-cerebrovascular accident/transient ischemic attack arterial thromboembolic event.
  • Central nervous system disease or dysfunction.
  • Requirement for > 2 anti-hypertensive medications.
  • Unwilling to refrain from alcohol consumption from Day 1 of admission to the in-patient facility until discharge from the facility.
  • Adrenal insufficiency.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Treatment and study plan

Bempegaldesleukin

Drug

Administered as an intravenous infusion

Other names: NKTR-214, BEMPEG

Standard of care

Drug

Standard of Care Treatment for COVID-19 Infection

Placebo

Other

Administered as an intravenous infusion

Primary outcomes

  1. AUC of Bempegaldesleukin [Pharmacokinetic Parameter].

    Time frame: Day 1: Predose, 0.5, 24, 48, 72, 120, and 168 hours post dose.

    Area under the serum concentration-time curve (AUC) of bempegaldesleukin calculated from time 0 to 168 hours.

  2. Cmax of Bempegaldesleukin [Pharmacokinetic Parameter].

    Time frame: Day 1: Predose, 0.5, 24, 48, 72, 120, and 168 hours post dose.

    Maximum observed serum concentration (Cmax) of bempegaldesleukin.

  3. Tmax of Bempegaldesleukin [Pharmacokinetic Parameter].

    Time frame: Day 1: Predose, 0.5, 24, 48, 72, 120, and 168 hours post dose.

    Time to maximum concentration of bempegaldesleukin. Cmax = maximum concentration. Tmax = time to maximum concentration.

  4. Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability]

    Time frame: Safety and tolerability were evaluated from baseline up to approximately 30 days.

    Safety and Tolerability of bempegaldesleukin (starting at dose 0.00075 mg/kg) in combination with SOC was evaluated by incidence of Treatment-Emergent Adverse Events of Any Grade, Grade 3-4, and Grade 5 (Death).

  5. Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)

    Time frame: The DLT evaluation period was up to approximately 7 days following the bempegaldesleukin treatment.

    Dose finding for this study was based on the assessment of DLT of bempegaldesleukin dose levels. Number and percentage of patients with any DLT were summarized by bempegaldesleukin dose level in bempegaldesleukin plus SOC treatment groups [0.00075 mg/kg, N=5; 0.0015 mg/kg, N=5; and 0.003 mg/kg, N=5] and placebo plus SOC (N=15).

    Adverse events related to study drug(s) that were defined as DLTs included the following:

    • Any Grade ≥ 3 drug-related AE.
    • Any Grade ≥ 3 drug-related laboratory abnormality that was clinically significant per the Investigator.
    • Respiratory compromise or other virus-related AE attributed to worsening COVID-19, such as severe hypoxia, cyanosis, or chest pain/pressure.

    The event was considered a DLT if it was confirmed to be at least possibly related to study drug, met any of the above definitions, and was confirmed to have occurred in a patient treated with bempegaldesleukin.

  6. Percent Change From Baseline for Absolute Lymphocyte Count (ALC) by Dose/Arm.

    Time frame: ALC was evaluated from baseline up to 7 days (Day 8) following the study drug administration.

    To assess the effect of bempegaldesleukin on the time course and extent of changes in absolute lymphocyte counts (ALC). Data are reported by dose and arm for Day 8 compared to baseline.

Secondary outcomes

  1. Percentage of Patients Who Require Supplemental Oxygen.

    Time frame: From baseline, following the administration of study drug approximately up to 30 days.

    The percentage of patients requiring supplemental oxygen was evaluated as part of disease measurements to assess efficacy.

    No patient in the study required supplemental oxygen.

  2. Change From Baseline on the Daily Collection World Health Organization (WHO) Clinical Progression Scale, an 11-point Clinical Status Ordinal Scale.

    Time frame: From baseline up to 7 days (Day 8) following the study drug administration.

    The WHO Clinical Progression Scale scores and descriptors are as follows: 0- Uninfected; no viral RNA detected; 1- Asymptomatic; viral RNA detected; 2- Symptomatic; independent; 3- Symptomatic; assistance needed; 4- Hospitalized, no oxygen therapy(a); 5- Hospitalized; oxygen by mask or nasal prongs ; 6- Hospitalized; oxygen by non-invasive ventilation or high-flow; 7- Intubation and mechanical ventilation, PaO2/FiO2 ≥ 150 or SpO2/FiO2 ≥ 200; 8- Mechanical ventilation, PaO2/FiO2 < 150 (SpO2/FiO2 < 200) or vasopressors; 9- Mechanical ventilation, PaO2/FiO2 < 150 and vasopressors, dialysis, or ECMO; 10- Death. The data are reported for Day 8 by arm. There were no scores rated 3 and higher per this scale at any timepoint.

    Abbreviations: ECMO = extracorporeal membrane oxygenation; FiO2 = fraction of inspired oxygen; PaO2 = partial pressure of arterial oxygen; SpO2 = oxygen saturation

    (a) If hospitalized for isolation only, record status as for ambulatory patient.

    Source: WHO 2020.

Sponsors and collaborators

Lead sponsor

Nektar Therapeutics

Industry

Registry information

Official study title

A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Mild COVID-19

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Nov 27, 2020
Registry last updated
Mar 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.